|
|
Blood, 15 July 2006, Vol. 108, No. 2, pp. 419-425.
Prepublished online as a Blood First Edition Paper on April 11, 2006; DOI 10.1182/blood-2005-10-4149.
 Previous Article | Table of Contents | Next Article 
PERSPECTIVES
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson,
Peter L. Greenberg,
John M. Bennett,
Bob Lowenberg,
Pierre W. Wijermans,
Stephen D. Nimer,
Antonio Pinto,
Miloslav Beran,
Theo M. de Witte,
Richard M. Stone,
Moshe Mittelman,
Guillermo F. Sanz,
Steven D. Gore,
Charles A. Schiffer, and
Hagop Kantarjian
From the Department of Hematology/Oncology, Georgetown University Hospital, Washington, DC; the Stanford University Cancer Center, CA; the James P. Wilmot Cancer Center at the University of Rochester Medical Center, NY; the Erasmus University Medical Center, Rotterdam, The Netherlands; the Ziekenhuis, Leynburg, The Hague, The Netherlands; the Centro di Riferimento Oncologico, Aviano, Italy; the Memorial Sloan-Kettering Cancer Center, New York, NY; the Department of Leukemia, University of Texas, M. D. Anderson Cancer Center, Houston; the Department of Hematology, Radboud University Nijmegen Medical Centre Central, Nijmegen, The Netherlands; the Dana-Farber Cancer Institute, Boston, MA; the Department of Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv University, Sackler School of Medicine, Tel Aviv, Israel; the Hospital Universitario La Fe, Valencia, Spain; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; the Karmanos Cancer Center, Wayne State University, Detroit, MI; and the Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston.
Abstract
The myelodysplastic syndromes (MDSs) are heterogeneous with respect to clinical characteristics, pathologic features, and cytogenetic abnormalities. This heterogeneity is a challenge for evaluating response to treatment. Therapeutic trials in MDS have used various criteria to assess results, making cross-study comparisons problematic. In 2000, an International Working Group (IWG) proposed standardized response criteria for evaluating clinically significant responses in MDS. These criteria included measures of alteration in the natural history of disease, hematologic improvement, cytogenetic response, and improvement in health-related quality of life. The relevance of the response criteria has now been validated prospectively in MDS clinical trials, and they have gained acceptance in research studies and in clinical practice. Because limitations of the IWG criteria have surfaced, based on practical and reported experience, some modifications were warranted. In this report, we present recommendations for revisions of some of the initial criteria.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. D. Schimmer, E. H. Estey, G. Borthakur, B. Z. Carter, G. J. Schiller, M. S. Tallman, J. K. Altman, J. E. Karp, J. Kassis, D. W. Hedley, et al.
Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia
J. Clin. Oncol.,
October 1, 2009;
27(28):
4741 - 4746.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Y. Follo, C. Finelli, S. Mongiorgi, C. Clissa, C. Bosi, N. Testoni, F. Chiarini, G. Ramazzotti, M. Baccarani, A. M. Martelli, et al.
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS
PNAS,
September 29, 2009;
106(39):
16811 - 16816.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Sekeres and D. P. Steensma
Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment
Blood,
September 24, 2009;
114(13):
2575 - 2580.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Greenberg, Z. Sun, K. B. Miller, J. M. Bennett, M. S. Tallman, G. Dewald, E. Paietta, R. van der Jagt, J. Houston, M. L. Thomas, et al.
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Blood,
September 17, 2009;
114(12):
2393 - 2400.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Steensma, M. R. Baer, J. L. Slack, R. Buckstein, L. A. Godley, G. Garcia-Manero, M. Albitar, J. S. Larsen, S. Arora, M. T. Cullen, et al.
Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
J. Clin. Oncol.,
August 10, 2009;
27(23):
3842 - 3848.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Keilholz, A. Letsch, A. Busse, A. M. Asemissen, S. Bauer, I. W. Blau, W.-K. Hofmann, L. Uharek, E. Thiel, and C. Scheibenbogen
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
Blood,
June 25, 2009;
113(26):
6541 - 6548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Raza, N. Galili, S. Smith, J. Godwin, J. Lancet, M. Melchert, M. Jones, J. G. Keck, L. Meng, G. L. Brown, et al.
Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome
Blood,
June 25, 2009;
113(26):
6533 - 6540.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Stone
How I treat patients with myelodysplastic syndromes
Blood,
June 18, 2009;
113(25):
6296 - 6303.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Perreault and J. Burzynski
Romiplostim: A novel thrombopoiesis-stimulating agent
Am. J. Health Syst. Pharm.,
May 1, 2009;
66(9):
817 - 824.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Ades, S. Boehrer, T. Prebet, O. Beyne-Rauzy, L. Legros, C. Ravoet, F. Dreyfus, A. Stamatoullas, M. Pierre Chaury, J. Delaunay, et al.
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study
Blood,
April 23, 2009;
113(17):
3947 - 3952.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Y. Follo, C. Finelli, C. Clissa, S. Mongiorgi, C. Bosi, G. Martinelli, M. Baccarani, L. Manzoli, A. M. Martelli, and L. Cocco
Phosphoinositide-Phospholipase C {beta}1 Mono-Allelic Deletion Is Associated With Myelodysplastic Syndromes Evolution Into Acute Myeloid Leukemia
J. Clin. Oncol.,
February 10, 2009;
27(5):
782 - 790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Komrokji and J. M. Bennett
What Is "WHO"?: Myelodysplastic Syndrome Classification and Prognosis
ASCO Educational Book,
January 1, 2009;
2009(1):
413 - 419.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Sekeres, J. P. Maciejewski, A. A.N. Giagounidis, K. Wride, R. Knight, A. Raza, and A. F. List
Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes
J. Clin. Oncol.,
December 20, 2008;
26(36):
5943 - 5949.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Schimmer, S. O'Brien, H. Kantarjian, J. Brandwein, B. D. Cheson, M. D. Minden, K. Yee, F. Ravandi, F. Giles, A. Schuh, et al.
A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies
Clin. Cancer Res.,
December 15, 2008;
14(24):
8295 - 8301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. R. Silverman, P. Fenaux, G. J Mufti, V. Santini, E. Hellstrom-Lindberg, N. Gattermann, G. Sanz, A. F. List, S. D. Gore, J. F Seymour, et al.
The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
227 - 227.
[Abstract]
|
|
|
|
|
|
|
P. A. Link, M. R. Baer, S. R. James, D. A. Jones, and A. R. Karpf
p53-Inducible Ribonucleotide Reductase (p53R2/RRM2B) Is a DNA Hypomethylation-Independent Decitabine Gene Target That Correlates with Clinical Response in Myelodysplastic Syndrome/Acute Myelogenous Leukemia
Cancer Res.,
November 15, 2008;
68(22):
9358 - 9366.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Sekeres, W. M. Schoonen, H. Kantarjian, A. List, J. Fryzek, R. Paquette, and J. P. Maciejewski
Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys
J Natl Cancer Inst,
November 5, 2008;
100(21):
1542 - 1551.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Tsai, S. M. Luger, C. Andreadis, D. T. Vogl, A. Kemner, M. Potuzak, A. Goradia, A. W. Loren, A. E. Perl, S. J. Schuster, et al.
A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia
Clin. Cancer Res.,
September 1, 2008;
14(17):
5619 - 5625.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Jadersten, L. Malcovati, I. Dybedal, M. Giovanni Della Porta, R. Invernizzi, S. M. Montgomery, C. Pascutto, A. Porwit, M. Cazzola, and E. Hellstrom-Lindberg
Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome
J. Clin. Oncol.,
July 20, 2008;
26(21):
3607 - 3613.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Sloand, C. O. Wu, P. Greenberg, N. Young, and J. Barrett
Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy
J. Clin. Oncol.,
May 20, 2008;
26(15):
2505 - 2511.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Klisovic, W. Stock, S. Cataland, M. I. Klisovic, S. Liu, W. Blum, M. Green, O. Odenike, L. Godley, J. V. Burgt, et al.
A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia
Clin. Cancer Res.,
April 15, 2008;
14(8):
2444 - 2449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Malcovati, M. Cazzola, and U. Germing
In Reply
J. Clin. Oncol.,
March 1, 2008;
26(7):
1181 - 1182.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Boehrer, L. Ades, T. Braun, L. Galluzzi, J. Grosjean, C. Fabre, G. Le Roux, C. Gardin, A. Martin, S. de Botton, et al.
Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study
Blood,
February 15, 2008;
111(4):
2170 - 2180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schmitt, A. Schmitt, M. T. Rojewski, J. Chen, K. Giannopoulos, F. Fei, Y. Yu, M. Gotz, M. Heyduk, G. Ritter, et al.
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses
Blood,
February 1, 2008;
111(3):
1357 - 1365.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kurzrock, H. M. Kantarjian, M. A. Blascovich, C. Bucher, S. Verstovsek, J. J. Wright, S. R. Pilat, J. E. Cortes, E. H. Estey, F. J. Giles, et al.
Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome
Clin. Cancer Res.,
January 15, 2008;
14(2):
509 - 514.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Park, S. Grabar, C. Kelaidi, O. Beyne-Rauzy, F. Picard, V. Bardet, V. Coiteux, G. Leroux, P. Lepelley, M.-T. Daniel, et al.
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience
Blood,
January 15, 2008;
111(2):
574 - 582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Raza, J. A. Reeves, E. J. Feldman, G. W. Dewald, J. M. Bennett, H. J. Deeg, L. Dreisbach, C. A. Schiffer, R. M. Stone, P. L. Greenberg, et al.
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
Blood,
January 1, 2008;
111(1):
86 - 93.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Siitonen, T. Timonen, E. Juvonen, V. Terava, A. Kutila, T. Honkanen, M. Mikkola, H. Hallman, M. Kauppila, P. Nylanden, et al.
Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes
Haematologica,
August 1, 2007;
92(8):
1119 - 1122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Fenaux, A. Raza, G. J. Mufti, C. Aul, U. Germing, H. Kantarjian, L. Cripe, R. Kerstens, P. De Porre, and R. Kurzrock
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome
Blood,
May 15, 2007;
109(10):
4158 - 4163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Estey
Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients
J. Clin. Oncol.,
May 10, 2007;
25(14):
1908 - 1915.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kantarjian, Y. Oki, G. Garcia-Manero, X. Huang, S. O'Brien, J. Cortes, S. Faderl, C. Bueso-Ramos, F. Ravandi, Z. Estrov, et al.
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Blood,
January 1, 2007;
109(1):
52 - 57.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Raza, F. Z. Raza, N. Galili, H. M. Kantarjian, Y. Oki, and J.-P. Issa
Low-dose decitabine and high-risk MDS
Blood,
December 15, 2006;
108(13):
4291 - 4292.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, G. Barosi, R. A. Mesa, F. Cervantes, H. J. Deeg, J. T. Reilly, S. Verstovsek, B. Dupriez, R. T. Silver, O. Odenike, et al.
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
Blood,
September 1, 2006;
108(5):
1497 - 1503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Schiffer
Clinical Issues in the Management of Patients with Myelodysplasia
Hematology,
January 1, 2006;
2006(1):
205 - 210.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
